The development of molecularly targeted therapies, as well as ICIs, has improved outcomes in the metastatic setting for NSCLC patients who harbor somatically activated oncogenes such as EGFR and BRAFV600, rearranged ALK or ROS1, or PD-L1 expression ≥50% of tumor cells [3,4,5]. Here, ROS1 is linked to neoplasm.